Global Regenerative Medicine Market is expected to foresee significant growth. APAC to lead the growth!

Regenerative medicine, including cell and gene therapy, harnesses the power of (stem) cells, biomaterials, molecules and genetic modification to repair, regenerate or replace diseased cells, tissues and organs. This approach is disrupting the traditional biotechnology and pharmaceutical industries with the promise of revolutionary new cures for devastating and costly conditions such as heart disease, diabetes, and cancer.

The Regenerative Medicine Market is expected to grow at a steady rate of around 17.5% during the forecast period (2022-2028) owing to a surge in the prevalence of cancer. According to GLOBOCAN, in 2020, there were about 19.3 million new cancer cases and approximately 10 million deaths. Thus, the surge in the incidences of cancer is expected to foster the adoption of regenerative medicines. Moreover, the rising initiatives of the government and various non-profit organizations in spreading awareness regarding the prevention of cancer are expected to fuel the growth of the market. For instance, the World Health Organization’s Global Action Plan for Prevention and Control of Non-Communicable Diseases aims at decreasing premature death due to cancer, cardiovascular diseases, chronic respiratory diseases, and diabetes by around 25% by the year 2025.

For a detailed analysis of the Global Regenerative Medicine Market browse through – https://univdatos.com/report/regenerative-medicine-market/

Based on product, the market is segmented into cell therapy, gene therapy, tissue engineering, and small molecule and biologics. Cell therapy held a dominant share in the market in 2021 with nearly 50 cell therapy-based regenerative products approved and marketed. A leading technical approach to cell therapy is the use of chimeric antigen receptor (CAR) T cells. These are engineered receptors that are grafted on to the T cell, a type of white blood cell that plays a key role in cell-mediated immunity. CAR T cells are increasingly being used to treat a host of diseases, including and especially cancer. For instance, in May 2022, U.S. FDA approved Kymriah CAR T-cell therapy for the management of adult patients with relapsed or refractory follicular lymphoma.

Based on material type, the global regenerative medicine market is segmented into synthetic materials, biologically derived materials, genetically engineered materials and others (pharmaceuticals). The genetically engineered materials is expected to grow with significant CAGR during the forecast period. Genetically engineered biomaterials have been a huge area of research over the last fifteen years and CRISPR has already started playing an important role in advancing biomaterial research. Elastin-like polypeptides (ELPs) are bioinspired polymers comprising short pentapeptide repeats found in natural elastin, with one of the most common being the pentapeptide sequence VPGXG, where X can be any amino acid except L-proline.

Based on application, the market is segmented into cardiovascular, oncology, dermatology, musculoskeletal, immunology and inflammation, ophthalmology, neurology, and others. The musculoskeletal category is expected to witness high CAGR during the forecast period. Regenerative medicine techniques aimed at the musculoskeletal system are increasingly translated to clinical trials and patient care. Currently, RM interventions are mostly developed for the early stage of disease with the aim to return these patients to a healthy state or slow disease progression. The focus of regenerative medicine has shifted to pluripotent stem cells (PSCs), namely, human embryonic stem cells and human-induced PSCs, due to the limited success of adult stem cell-based interventions.

Request for a sample of the report browse through- https://univdatos.com/get-a-free-sample-form-php/?product_id=10756

For a better understanding of the market adoption of the regenerative medicine industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is anticipated to grow at a substantial CAGR during the forecast period mainly due to the surge in the prevalence of various cancers. According to the report titled “Cancer statistics in China and U.S., 2022: profiles, trends, and determinants” published in February 2022, compared to the 4,568,754 new cancer cases in China in 2020, the predicted number of new cancer cases for 2022 is 4,820,000. This increase in the new cases will directly increase the demand for cancer therapy, thus helping in the growth of the market during the study period. Moreover, domestic companies are also tremendously investing to gain a competitive edge in the market. For instance, in October 2022, Symex Corporation and JCR Pharmaceuticals established a joint venture for carrying out research and development, manufacture, and sales of cell-based regenerative medicine products including hematopoietic stem cells and other stem cells.

Some of the major players operating in the market include Athersys, Inc., Corline Biomedical AB, Mesoblast, Nuvasive, Inc., Cook Biotech, Integra LifeSciences Corporation, Organogenesis, Osiris Therapeutics, Inc., Stryker Corporation, and U.S. Stem Cell, Inc.

Global Regenerative Medicine Market Segmentation

Market Insight, by Product

· Cell Therapy

· Gene Therapy

· Tissue Engineering

· Small Molecules and Biologics

Market Insight, by Material Type

· Synthetic Material

· Biologically Derived Materials

· Genetically Engineered Materials

· Others (Pharmaceuticals)

Market Insight, by Application

· Cardiovascular

· Oncology

· Dermatology

· Musculoskeletal

· Immunology and Inflammation

· Ophthalmology

· Neurology

· Others

Market Insight, by Region

· North America

o U.S.

o Canada

o Rest of North America

· Europe

o Germany

o United Kingdom

o France

o Italy

o Spain

o Rest of Europe

· Asia-Pacific

o China

o Japan

o India

o Rest of Asia-Pacific

· Rest of the World

Top Company Profiles

· Athersys, Inc

· Corline Biomedical AB

· Mesoblast

· NuVasive, Inc.

· Cook Biotech

· Integra LifeSciences

· Organogenesis

· Osiris Therapeutics, Inc

· Stryker Corporation

· U.S. Stem Cell Inc.